Darinaparsin

A novel organic arsenical with promising anticancer activity

Koren K. Mann, Barbara Wallner, Izidore Lossos, Wilson H. Miller

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Darinaparsin is an organic arsenical composed of dimethylated arsenic linked to glutathione, and is being investigated for antitumor properties in vitro and in vivo. While other arsenicals, including arsenic trioxide, have been used clinically, none have shown significant activity in malignancies outside of acute promyelocytic leukemia. Darinaparsin has significant activity in a broad spectrum of hematologic and solid tumors in preclinical models. Here, we review the literature describing the signaling pathways and mechanisms of action of darinaparsin and compare them to mechanisms of cell death induced by arsenic trioxide. Darinaparsin has overlapping, but distinct, signaling mechanisms. We also review the current results of clinical trials with darinaparsin (both intravenous and oral formulations) that demonstrate significant antitumor activity.

Original languageEnglish
Pages (from-to)1727-1734
Number of pages8
JournalExpert Opinion on Investigational Drugs
Volume18
Issue number11
DOIs
StatePublished - Nov 1 2009

Fingerprint

Arsenicals
Acute Promyelocytic Leukemia
Arsenic
Glutathione
Neoplasms
Cell Death
darinaparsin
Clinical Trials

Keywords

  • Apoptosis
  • Arsenic
  • Darinaparsin
  • Lymphoma
  • Mitochondria
  • Reactive oxygen species

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Darinaparsin : A novel organic arsenical with promising anticancer activity. / Mann, Koren K.; Wallner, Barbara; Lossos, Izidore; Miller, Wilson H.

In: Expert Opinion on Investigational Drugs, Vol. 18, No. 11, 01.11.2009, p. 1727-1734.

Research output: Contribution to journalArticle

Mann, Koren K. ; Wallner, Barbara ; Lossos, Izidore ; Miller, Wilson H. / Darinaparsin : A novel organic arsenical with promising anticancer activity. In: Expert Opinion on Investigational Drugs. 2009 ; Vol. 18, No. 11. pp. 1727-1734.
@article{e577847c8913427792282119f976ffd2,
title = "Darinaparsin: A novel organic arsenical with promising anticancer activity",
abstract = "Darinaparsin is an organic arsenical composed of dimethylated arsenic linked to glutathione, and is being investigated for antitumor properties in vitro and in vivo. While other arsenicals, including arsenic trioxide, have been used clinically, none have shown significant activity in malignancies outside of acute promyelocytic leukemia. Darinaparsin has significant activity in a broad spectrum of hematologic and solid tumors in preclinical models. Here, we review the literature describing the signaling pathways and mechanisms of action of darinaparsin and compare them to mechanisms of cell death induced by arsenic trioxide. Darinaparsin has overlapping, but distinct, signaling mechanisms. We also review the current results of clinical trials with darinaparsin (both intravenous and oral formulations) that demonstrate significant antitumor activity.",
keywords = "Apoptosis, Arsenic, Darinaparsin, Lymphoma, Mitochondria, Reactive oxygen species",
author = "Mann, {Koren K.} and Barbara Wallner and Izidore Lossos and Miller, {Wilson H.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1517/13543780903282759",
language = "English",
volume = "18",
pages = "1727--1734",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Darinaparsin

T2 - A novel organic arsenical with promising anticancer activity

AU - Mann, Koren K.

AU - Wallner, Barbara

AU - Lossos, Izidore

AU - Miller, Wilson H.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Darinaparsin is an organic arsenical composed of dimethylated arsenic linked to glutathione, and is being investigated for antitumor properties in vitro and in vivo. While other arsenicals, including arsenic trioxide, have been used clinically, none have shown significant activity in malignancies outside of acute promyelocytic leukemia. Darinaparsin has significant activity in a broad spectrum of hematologic and solid tumors in preclinical models. Here, we review the literature describing the signaling pathways and mechanisms of action of darinaparsin and compare them to mechanisms of cell death induced by arsenic trioxide. Darinaparsin has overlapping, but distinct, signaling mechanisms. We also review the current results of clinical trials with darinaparsin (both intravenous and oral formulations) that demonstrate significant antitumor activity.

AB - Darinaparsin is an organic arsenical composed of dimethylated arsenic linked to glutathione, and is being investigated for antitumor properties in vitro and in vivo. While other arsenicals, including arsenic trioxide, have been used clinically, none have shown significant activity in malignancies outside of acute promyelocytic leukemia. Darinaparsin has significant activity in a broad spectrum of hematologic and solid tumors in preclinical models. Here, we review the literature describing the signaling pathways and mechanisms of action of darinaparsin and compare them to mechanisms of cell death induced by arsenic trioxide. Darinaparsin has overlapping, but distinct, signaling mechanisms. We also review the current results of clinical trials with darinaparsin (both intravenous and oral formulations) that demonstrate significant antitumor activity.

KW - Apoptosis

KW - Arsenic

KW - Darinaparsin

KW - Lymphoma

KW - Mitochondria

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=73849095467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849095467&partnerID=8YFLogxK

U2 - 10.1517/13543780903282759

DO - 10.1517/13543780903282759

M3 - Article

VL - 18

SP - 1727

EP - 1734

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 11

ER -